pdufa.bio

neffy (epinephrine nasal spray)

Page updated ·next FDA decision on the calendar ·Data as of Oct 15, 2026 10:03 PM ET

neffy (epinephrine nasal spray) The FDA approved it on Mar 27, 2026. 1 FDA decision on record below. Every date links its source.

SPRY catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

We track 1 catalyst event for this program: 0 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

FDA decision · Mar 27, 2026 ✓ ApprovedSPRY

Specialist biotech funds holding SPRY, 13F for the quarter ended June 30, 2026

FundSharesValue at quarter endFiling
RA Capital Management10,860,977$87.0 millionfiled August 14, 2026
OrbiMed Advisors8,288,510$66.4 millionfiled August 14, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is neffy (epinephrine nasal spray)'s next FDA decision or readout?

No upcoming catalyst is on our calendar for neffy (epinephrine nasal spray); 1 FDA decision is on record below.

What happened at neffy (epinephrine nasal spray)'s most recent FDA decision?

On Mar 27, 2026 the FDA approved the application. The decision page carries the source document and the measured share-price reaction.

Has neffy (epinephrine nasal spray) been approved by the FDA?

Yes. The FDA approved an application for neffy (epinephrine nasal spray) on Mar 27, 2026; the decision page linked above carries the source.

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.